hims and hers glp 1 reviews weight loss review 2026 Hims & Hers Weight Loss

Consider using CGM to assess glycaemic response to foods (especially if you were glucose dysregulated before) Expected outcomes: Appetite reduction, 25% waist circumference and weight loss, early visceral fat reduction, improved post-meal glucose responses Month 35: Acceleration Phase Reach therapeutic steady GLP-1 dose Use CGM data to guide food choices where necessary Resistance training becomes part of routine and needs to be progressive (ie once strength improves and it becomes easy, lift heavier weights) Waist circumference continues to drop, even if weight remains steady (as muscle weighs more than adipose tissue) Likely improvement in glycaemic and MASLD blood markers Expected outcomes: 510% total body weight loss, increased insulin sensitivity, improved energy levels, lowered blood pressure Month 68: Transition Phase Emphasis shifts to muscle preservation and metabolic independence Protein intake and strength training remain central For those reaching waist goals, begin tapering GLP-1 dose under supervision Expected outcomes: Stable lean mass, reduced visceral fat, better metabolic flexibility, readiness to stop medication How Do We Measure Success

If a lump remains hard, grows, or becomes increasingly painful, seek medical evaluation to rule out infection or other complications

Stop looking at milligrams and start asking: How does this get into my blood

Deaktivieren Sie sie, wird Ihnen stattdessen andere Werbung angezeigt

A network meta-analysis published in 2025 confirmed retatrutide demonstrated greater absolute weight reduction compared to tirzepatide across comparable timeframes